Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research note issued to investors on Monday. The firm set a “sell” rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Trading Up 0.6 %

NASDAQ:CYCC opened at $0.80 on Monday. The stock has a market capitalization of $1.72 million, a P/E ratio of -0.05 and a beta of 0.51. Cyclacel Pharmaceuticals has a 1 year low of $0.75 and a 1 year high of $11.34. The firm has a 50 day moving average of $1.11 and a 200-day moving average of $1.63.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.11. Cyclacel Pharmaceuticals had a negative return on equity of 1,901.11% and a negative net margin of 21,963.75%. During the same period in the prior year, the business posted ($6.60) earnings per share. As a group, analysts forecast that Cyclacel Pharmaceuticals will post -2.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Cyclacel Pharmaceuticals

A hedge fund recently bought a new stake in Cyclacel Pharmaceuticals stock. Armistice Capital LLC purchased a new stake in shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned about 9.18% of Cyclacel Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 23.58% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.